Fundraising FoxBobcatBio
Hummelstown, US · Founded 2020 · Delaware corporation · 3 known investors
Find your way into BobcatBio
Sign up to see every warm intro you have to BobcatBio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the BobcatBio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
SC
Stephen C. RocamboliExecutiveStephen C. Rocamboli served as Chief Business Officer of Candel Therapeutics, where he managed corporate strategy and helped grow the company to 50 employees while overseeing multiple oncology clinical trials and securing $80 million in private financing. Earlier, he worked as a senior executive and legal counsel on Wall Street, where he completed large-scale life sciences financing transactions and co-founded multiple biotech companies including Javelin Pharmaceuticals, Chelsea Therapeutics International, Cougar Biotechnology, and Cutanea Life Sciences.
RP
Rifat PamukcuNamed on SEC filing
RT
Robert TowarnickiNamed on SEC filing
RS
Roger SawhneyNamed on SEC filing
Board
TV
JF
Investors · 3
BioAdvancelisted by BioAdvanceConshohocken · $500K – $1.5M
How we know: BioAdvance's portfolio page · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$32.4M disclosed across 2 rounds · 2021–2025
▶$5.3MraisedMar 2025 · 11 investors · BiotechnologyRule 506(b)
▶$5.3MraisedMar 2025 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Roger SawhneyDirector
- Tim Van TreurenDirector
- Rifat PamukcuDirector
- Stephen C. RocamboliExecutive Officer, Director
- Robert TowarnickiDirector
- Offering amount
- $15M
- Amount sold
- $5.3M
- Proceeds to insiders
- $323K
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$27.1MraisedJan 2024 · 10 investors · BiotechnologyRule 506(b)
▶$27.1MraisedJan 2024 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tim Van TreurenDirector
- Rifat PamukcuDirector
- John FucciDirector
- Robert TowarnickiExecutive Officer, Director
- Roger SawhneyDirector
- Offering amount
- $42.1M
- Amount sold
- $27.1M
- Proceeds to insiders
- $550K
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are BobcatBio's investors?
- BobcatBio's investors include BioAdvance, Life Sciences Greenhouse Investments, Bios Partners.
- How much funding has BobcatBio raised?
- BobcatBio has disclosed $32.4M raised across 2 rounds.
- Where is BobcatBio headquartered?
- BobcatBio is headquartered in Hummelstown, US.